Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus EXSEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus EXSEL.
AUKELSO vs EXSEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
400 mg orally twice daily with food.
1-2 mg orally once daily; maximum dose 2 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Topical Antifungal
Topical Antifungal